Market Trends of Artificial Kidney Industry
Wearable Artificial Kidney Segment is Expected to Hold a Significant Share in Market Over the Forecast Period
Wearable artificial kidneys are a sort of portable medical technology that allows patients to benefit from dialysis at home while going about their daily activities. This gadget improves the lives of patients with end-stage renal disease by eliminating hospital stays and enhancing physiological aspects by lowering hypertension. It reduces sodium retention as well as the risk of stroke and vascular disease, and it is less expensive than alternative medications for renal failure patients. The segment is driven by the rising prevalence of kidney diseases and strategic initiatives by market players, such as regulatory approval and product launches.
Wearable/portable kidneys improve dialysis by allowing for home dialysis and improving frequency and autonomy, which leads to an increase in the demand for wearable kidneys over the implantable kidney. Home dialysis has advantages over in-centre hemodialysis and has the potential to save the healthcare system money. There are several portable home hemodialysis systems available, including the NxStage System One (NxStage Medical Inc.), the 2008K home (Fresenius Medical Care), and the SC+ hemodialysis system (Quanta).
The regulatory authority's clearance of the wearable artificial kidney may expand market introduction and end-user access, supporting segment growth. For instance, in May 2021, the United States Patent and Trademark Office granted a patent to Victor Gura, MD, FASN, for a wearable artificial kidney, and the nephrologist said he would begin clinical trials for the device in the next few years. Additionally, the growing focus of market players on developing wearable artificial kidneys, which are expected to launch in the market, is expected to boost the market growth. For instance, in February 2023, NextKidney, a medical equipment firm that created the first portable hemodialysis machine, raised GBP 11.9 million (USD 14.82 million) in a Series B round of funding. NextKidney will use the funds for clinical trials and market clearance of the company's portable artificial kidney device.
Thus, all aforementioned factors, such as the growing burden of kidney diseases and regulatory approval and funding activities, are expected to boost the segment's growth over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to witness a significant market share in the artificial kidney market over the forecast period. The major factors driving the market growth are the rising prevalence of chronic kidney diseases, the presence of well-established healthcare infrastructure along with high health spending, and technologically advanced products.
The growing burden of kidney diseases, which lead to kidney damage or failure, is likely to increase the demand for artificial kidneys. For instance, according to the National Institutes of Health data updated in September 2021, chronic kidney disease (CKD) affects nearly one-seventh of all adults in the United States (i.e., 37 million people). The risk of CKD is much higher for Americans with diabetes or high blood pressure, the two most frequent causes of kidney disease. Kidney disease affects nearly one-third of diabetics and one-fifth of those with high blood pressure. Heart disease and a family history of renal failure are two more risk factors for kidney disease. Patients with end-stage renal disease (ESRD) usually have a small bladder capacity and increased bladder sensation.
There has been a dramatic increase in focus on the development of the artificial kidney. For instance, in August 2022, the Kidney Innovation Accelerator will give USD 10.5 million to the American Society of Nephrology and the United States Department of Health and Human Services for a new prize competition. Similarly, in September 2021, the U.S. Department of Health and Human Services and the American Society of Nephrology announced the winners of Phase 1 of the KidneyX Artificial Kidney Prize based on their potential to advance the functionality, effectiveness, and reliability of the artificial kidney.
Thus, all aforementioned factors, such as the growing burden of chronic kidney diseases and the growing focus on the development of artificial kidneys, are expected to boost the market over the forecast period.
